Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics (NASDAQ: RNTX) announced upcoming presentations at the IPF Summit 2025 in Boston, MA, from August 19-21, 2025. Chief Scientific Officer Cory Hogaboam will present on the role of lung-resident macrophages in IPF and the potential of Caveolin-scaffolding domain (CSD) peptides in treating the disease.
CEO Brian Windsor will discuss the company's Phase 2 trial of LTI-03, which will enroll up to 120 patients to evaluate safety, tolerability, and lung function outcomes. The trial represents Rein's innovative approach to addressing IPF through a multi-pathway strategy aimed at not just slowing fibrosis but potentially improving patient outcomes.
Rein Therapeutics (NASDAQ: RNTX) ha annunciato presentazioni previste all'IPF Summit 2025 a Boston, MA, dal 19 al 21 agosto 2025. Il Chief Scientific Officer Cory Hogaboam parlerà del ruolo dei macrofagi residenti nel polmone nella IPF e del potenziale terapeutico dei peptidi del Caveolin-scaffolding domain (CSD).
Il CEO Brian Windsor esporrà i dettagli del trial di Fase 2 di LTI-03, che arruolerà fino a 120 pazienti per valutare sicurezza, tollerabilità e parametri di funzionalità polmonare. Lo studio rappresenta l'approccio innovativo di Rein per affrontare l'IPF con una strategia multi-via volta non solo a rallentare la fibrosi, ma anche a migliorare i risultati clinici dei pazienti.
Rein Therapeutics (NASDAQ: RNTX) anunció presentaciones en el IPF Summit 2025 en Boston, MA, del 19 al 21 de agosto de 2025. El Director Científico Cory Hogaboam hablará sobre el papel de los macrófagos residentes en el pulmón en la IPF y el potencial de los péptidos del Caveolin-scaffolding domain (CSD) para tratar la enfermedad.
El CEO Brian Windsor presentará el ensayo de Fase 2 de LTI-03, que reclutará hasta 120 pacientes para evaluar seguridad, tolerabilidad y resultados de función pulmonar. El ensayo refleja el enfoque innovador de Rein para abordar la IPF mediante una estrategia multipathway destinada no solo a frenar la fibrosis, sino también a mejorar los desenlaces de los pacientes.
Rein Therapeutics (NASDAQ: RNTX)는 2025년 8월 19일부터 21일까지 매사추세츠주 보스턴에서 열리는 IPF Summit 2025에서 발표를 예정하고 있다고 발표했습니다. 최고 과학 책임자 코리 호가붐(Cory Hogaboam)은 폐에 상주하는 대식세포의 IPF에서의 역할과 Caveolin-scaffolding domain(CSD) 펩타이드의 치료 가능성에 대해 발표합니다.
CEO 브라이언 윈저(Brian Windsor)는 최대 120명의 환자를 등록하여 안전성, 내약성 및 폐기능 결과를 평가하는 LTI-03의 2상 시험에 대해 설명할 예정입니다. 이 시험은 섬유증 진행을 늦추는 것을 넘어 환자 결과 개선을 목표로 하는 다중 경로 전략이라는 Rein의 혁신적 접근을 보여줍니다.
Rein Therapeutics (NASDAQ: RNTX) a annoncé des présentations prévues au IPF Summit 2025 à Boston, MA, du 19 au 21 août 2025. Le Chief Scientific Officer Cory Hogaboam abordera le rôle des macrophages résidents pulmonaires dans la FPI et le potentiel des peptides du Caveolin-scaffolding domain (CSD) pour traiter la maladie.
Le CEO Brian Windsor présentera l'essai de phase 2 de LTI-03, qui recrutera jusqu'à 120 patients afin d'évaluer la sécurité, la tolérabilité et les paramètres de fonction pulmonaire. Cet essai illustre l'approche innovante de Rein, visant via une stratégie multi-voies à non seulement ralentir la fibrose, mais aussi à améliorer potentiellement les résultats pour les patients.
Rein Therapeutics (NASDAQ: RNTX) gab bekannt, dass es vom 19. bis 21. August 2025 Präsentationen auf dem IPF Summit 2025 in Boston, MA, geben wird. Chief Scientific Officer Cory Hogaboam wird über die Rolle der in der Lunge ansässigen Makrophagen bei IPF und das Potenzial von Caveolin-scaffolding domain (CSD)-Peptiden zur Behandlung der Erkrankung sprechen.
CEO Brian Windsor wird die Phase-2-Studie zu LTI-03 vorstellen, die bis zu 120 Patienten einschreiben soll, um Sicherheit, Verträglichkeit und Lungenfunktionsparameter zu untersuchen. Die Studie steht für Reins innovativen, multi-pathway Ansatz, der darauf abzielt, Fibrose nicht nur zu verlangsamen, sondern möglicherweise auch die Patientenergebnisse zu verbessern.
- None.
- None.
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA.
Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, “Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation.” He will discuss:
- The role of key immune cells in idiopathic pulmonary fibrosis (IPF) called lung-resident macrophages.
- How macrophage modulation may be critical to stopping the disease from getting worse.
- How Caveolin-scaffolding domain (CSD) peptides, the class of molecules Rein is advancing, target multiple drivers of fibrosis and could potentially help repair lung tissue.
Dr. Windsor’s presentation, “Innovating Clinical Trial Design in IPF: Lessons from LTI-03,” will take place at 9:30 am on Thursday. He will provide:
- An overview of Rein’s Phase 2 trial of LTI-03, which will enroll up to 120 patients, assess safety and tolerability, and focus on lung function as a key outcome.
- A discussion of trial design, strategies around patient recruitment, and how Rein is working to make the study feasible and relevant in a fast-changing treatment landscape.
Dr. Windsor commented, “IPF remains a devastating and complex disease with significant unmet need. Our mission is not just to slow fibrosis, it’s to give patients a real chance to improve. We believe our multi-pathway approach offers something fundamentally different.”
The IPF Summit 2025 is a leading global event focused on advancing treatments for this deadly lung disease. It brings together leading scientists, clinicians, industry executives, and patient advocates to share advancements in the understanding and treatment of IPF and related interstitial lung diseases.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. and is in clinical development. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
Forward-Looking Statements
This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to future expectations, plans and prospects for Rein. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as well as the risks and uncertainties discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Rein Investor Relations & Media Contact:
Investor Relations
IR@ReinTx.com
FAQ
When and where will Rein Therapeutics (RNTX) present at IPF Summit 2025?
What is the focus of Rein Therapeutics' Phase 2 trial for LTI-03?
How does Rein Therapeutics' approach to treating IPF differ from others?
What will Dr. Hogaboam's presentation cover at the IPF Summit 2025?
